Skip to Content
  • Previous Rank
    13
  • Revenues ($M)
    $214,319.00
  • Revenue Percent Change
    2.9%
  • Profits ($M)
    $34
  • Profits Percent Change
    -49.3%
  • Assets ($M)
    $59,672.00
  • Employees
    70,000

America’s largest drug distributor is under new leadership after John Hammergren, its long-serving CEO—and consistently one of the country’s highest paid—retired in April. He left the wholesaler much expanded from when he began his run at the company 17 years ago. That trend continued in 2018: Revenue grew 2.9% due to rising drug prices, increased sales to existing customers, and through acquisitions. Profits took a hit partly because of one-time charges involving its European business and Rexall, a Canadian drug store chain McKesson acquired in 2016. Like its two major competitors, McKesson is facing a growing number of lawsuits for its alleged role in the nation’s opioid epidemic; it has denied any wrongdoing.

41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Information

CEO
Brian S. Tyler
Sector
Health Care
Industry
Wholesalers: Health Care
HQ Location
Irving, Texas
Websitehttps://www.mckesson.com
Years on Global 500 List25
Employees70,000
Figures are for fiscal year ended March 31, 2019.

McKesson Rank History

placeholder

Key Financials (Last Fiscal Year)

($ Millions)% change
Revenues ($M)$214,319.002.9%
Profits ($M)$34-49.3%
Assets ($M)$59,672.00-
Total Stockholder Equity ($M)$8,094.00-

Profit Ratios

Profit as % of Revenues-
Profits as % of Assets0.1%
Profits as % of Stockholder Equity0.4%